Coverage
-
April 09, 2015
The Federal Circuit on Thursday affirmed a lower court's ruling barring Sandoz Inc. from marketing a generic version of the eye infection drug AzaSite, ruling that the company has failed to show that patents owned by Pfizer Inc. and others are invalid as obvious.
1 other articles on this case.
View all »